CD274 and liver cancer: Additionally, multiple phase II/III clinical trials are ongoing in lung cancer, liver cancer, kidney cancer, gastrointestinal tumors, and HNSCC with anti-TIGIT/anti-PD-1/anti-PD-L1 combined with chemotherapy, and we look forward to the results of these trials in the future[49].